Recombinant (or genetically engineered) protein expression systems are used to produce large quantities of highly purified human proteins for clinical use. The yield of purified protein that a commercial production system is capable of producing is largely determined by the quality of the cell line used. A cell line is essentially a genetically engineered population […]
Rita Jervis
CORPORATE CONTACT
Dragon Pharmaceuticals Inc.
Rita Jervis
Tel: (604) 669-8817
Email:
Steroid.biz Supplier
This isnt my first time ordering from Steroid.biz and definitely wont be my last. They definitely have improved on pretty much everything,especially the time of arrival for my orders. The first time I ordered from Steroid.biz, even though it was a few years ago,it took about a month at least for me to get my […]
Dragon Strengthens its European Presence
Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) is pleased to announce that the Company has strengthened its European presence by appointing an additional key executive in the newly established European office to focus on capturing European business opportunities through the execution of the Company’s European strategy. The Company has appointed Dr. Rene A. Fricker […]
Financial Results for the Third Quarter of 2005
Dragon Pharmaceutical Inc. (“Dragon”or the “Company” (TSX: DDD; OTC BB: DRUG) today announced the financial results for the quarter ended September 30, 2005. Financial Summary Dragon reported sales of $13.34 million for the third quarter ended September 30, 2005, an increase of 82% compared to the third quarter of 2004, and 18% increase sequentially from […]
Dragon Announces Appointment of General Manager of Chinese Operations
Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD) today announced the appointment of Mr. Xiaochun Zhang as the General Manager of the Company’s Chinese operations. As the General Manager of our Chinese operations, Mr. Zhang is responsible for the overall operational and sales and marketing management of the Pharma and Chemical divisions. Such responsibilities will […]
Dragon Announces Results of the Annual General Meeting
Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD) (“the Company”) is pleased to announce the results of the Annual Shareholders. Meeting held on August 12, 2005. There were 54,818,706 shares equaling 87.20% of the outstanding shares represented at this meeting. All of the following proposals were approved by a substantial majority of votes: Election of […]
Dragon Appoints Ernst & Young LLP as Company’s Auditor
Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD; BBSE: DRP) (“the Company”) is pleased to announce the appointment of Ernst & Young LLP (“Ernst & Young”) by its Board of Directors as the Company’s independent registered public accounting firm. In addition, the Board also approved the filing of a listing application with the American Stock […]
Dragon Pharmaceutical Announces Restatement of Oriental Wave’s Financial Statements
Dragon Pharmaceutical Inc. (“Dragon” or the “Company” (TSX: DDD; OTC BB: DRUG) announced today that, as a result of a review of its accounting policies and applicable accounting pronouncements, the Company has concluded that the reduction of a future retirement benefit obligation related to the acquisition of a land use right from an unrelated former […]
Dragon Announces Date set for 2005 Annual Stockholder Meeting
Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD; BBSE: DRP) (“the Company”) is pleased to announce that August 12, 2005 has been set as the date for the annual stockholder meeting of the Company. The annual meeting of Dragon stockholders will be held at Dragon’s corporate offices at Suite 1900, 1055 West Hastings Street, Vancouver, […]
Worldwide Licensing Rights, excluding China, for Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)
Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced that it has entered into an agreement with Suzhou Zhongkai Bio-Pharmaceuticals Company Limited (“Zhongkai”) to in-license the exclusive right to commercialize its Recombinant Human Granulocyte Colony Stimulating Factor (“rhG-CSF? product worldwide, excluding the People’s Republic of China (the “Agreement”). Using a non-mammalian cell fermentation technique […]
